Low-Dose Colchicine for Cardiovascular Event Reduction: What the Evidence Shows for Primary Care
Synthesis of 12 studies — including 6 RCTs, 4 meta-analyses, and the 2023 AHA/ACC guideline — evaluating colchicine 0.5 mg daily for secondary prevention in atherosclerotic cardiovascular disease. Strong evidence base, through 2025.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Strong evidence from the LoDoCo2 (n = 5522) and COLCOT (n = 4745) trials supports low-dose colchicine (0.5 mg daily) for reducing major cardiovascular events by 23–31% in patients with established coronary artery disease already receiving guideline-directed therapy including statins.
- A 2025 updated meta-analysis of 6 RCTs confirmed a 25% reduction in the primary cardiovascular composite endpoint with colchicine, despite inclusion of the neutral CLEAR-SYNERGY trial — supporting the robustness of the treatment effect.
- The FDA approved colchicine 0.5 mg (Lodoco) in June 2023 as the first anti-inflammatory drug indicated for cardiovascular risk reduction, and the 2023 AHA/ACC guideline gives a Class 2b recommendation for patients with chronic coronary disease at very high risk despite optimised therapy.
- No trial has demonstrated a reduction in all-cause mortality, and a numerically higher rate of non-cardiovascular death with colchicine in some trials — though not statistically significant in the largest studies — warrants careful patient selection, awareness of drug interactions (CYP3A4/P-gp inhibitors), and renal/hepatic monitoring.
Why Low-Dose Colchicine for Cardiovascular Prevention Matters
Despite aggressive lipid-lowering with statins, antiplatelet therapy, and revascularisation, patients with established atherosclerotic cardiovascular disease (ASCVD) carry substantial residual risk. A 2023 analysis of over 31 000 statin-treated patients demonstrated that residual inflammation — measured by high-sensitivity C-reactive protein (hsCRP) — is a stronger predictor of future cardiovascular events and death than residual cholesterol burden. This “inflammatory gap” represents a therapeutic target that has been largely unaddressed in routine primary care practice.
The June 2023 FDA approval of colchicine 0.5 mg (Lodoco) marked the first time an anti-inflammatory drug received regulatory endorsement specifically for cardiovascular risk reduction. For family physicians managing chronic coronary disease, this represents a genuinely new therapeutic lever — an inexpensive, oral, once-daily medication that addresses a distinct pathophysiological pathway. However, adoption has been slow: one health system analysis found that fewer than 1% of eligible patients with coronary artery disease had been prescribed colchicine by mid-2023. Understanding the evidence — including both the benefits and the unresolved safety signals — is essential for informed prescribing decisions in primary care.
What Evidence Was Reviewed
This synthesis draws on 6 randomised controlled trials, 4 meta-analyses, a population impact analysis, and the 2023 AHA/ACC guideline. The evidence spans patients with chronic coronary syndrome, recent myocardial infarction, acute coronary syndrome, and prior stroke — all treated with colchicine 0.5 mg daily on top of guideline-directed medical therapy.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| LoDoCo2 (Nidorf 2020, NEJM) | RCT | 5522 | Stable CAD ≥6 mo post-ACS | 31% MACE reduction (HR 0.69, 95% CI 0.57–0.83) | High |
| COLCOT (Tardif 2019, NEJM) | RCT | 4745 | Within 30 d post-MI | 23% MACE reduction (HR 0.77, 95% CI 0.61–0.96); stroke HR 0.26 | High |
| LoDoCo (Nidorf 2013) | RCT (open-label) | 532 | Stable CAD | 67% reduction in CV events (HR 0.33, 95% CI 0.18–0.59) | Moderate |
| CLEAR-SYNERGY (Jolly 2025, NEJM) | RCT (2×2 factorial) | 7062 | ACS + PCI | Neutral: MACE 9.1% vs 9.3% (HR 0.99, 95% CI 0.85–1.16) | High |
| COPS (Tong 2020) | RCT | 795 | Acute coronary syndrome | Neutral on primary endpoint; higher non-CV death with colchicine | Moderate |
| CONVINCE (2024) | RCT | NR | Post-stroke/TIA | Evaluated colchicine for stroke secondary prevention | Moderate |
| Fiolet 2021 MA (Eur Heart J) | MA of 4 RCTs | 11816 | CAD (stable + post-MI) | 25% reduction in MI/stroke/CV death (HR 0.75, 95% CI 0.61–0.92) | High |
| 2025 Updated MA (Eur Heart J) | MA of 6 RCTs | NR | All colchicine CV trials | 25% reduction persists even including CLEAR-SYNERGY | High |
| JACC Review 2023 (Ridker) | Review | NR | Comprehensive colchicine review | Colchicine reduces MI/stroke/CV death by 25%; stroke by 46% | High |
| LoDoCo2 Risk Subanalysis (2025) | Secondary analysis | 5522 | CCS by baseline risk | Benefit consistent across risk strata; greatest absolute benefit in highest-risk patients | Moderate |
| Population Impact Study (2025) | Retrospective + modelling | 9200000 | US adults with stable CAD on statin | Estimated 226 000 MACE preventable over 3 years with broad colchicine adoption | Moderate |
| AHA/ACC 2023 Guideline | CPG | NR | Chronic coronary disease | Class 2b recommendation: colchicine may be considered for very high-risk patients on max GDMT | High |
Key Findings on Low-Dose Colchicine for Cardiovascular Prevention
Consistent MACE Reduction in Stable CAD and Post-MI Settings
The two pivotal trials — LoDoCo2 and COLCOT — independently demonstrated that adding colchicine 0.5 mg daily to optimised guideline-directed medical therapy reduced the composite of major adverse cardiovascular events by 31% and 23%, respectively. In LoDoCo2, the primary composite of cardiovascular death, spontaneous MI, ischaemic stroke, or ischaemia-driven revascularisation occurred in 6.8% of the colchicine group compared with 9.6% of placebo (HR 0.69, 95% CI 0.57–0.83; 2.5 vs 3.6 events per 100 person-years). In COLCOT, benefits were driven primarily by reductions in stroke (HR 0.26, 95% CI 0.10–0.70) and angina requiring revascularisation (HR 0.50, 95% CI 0.31–0.81). Both trials enrolled patients already receiving statins (96–99%) and antiplatelet therapy.
The 2021 Fiolet meta-analysis pooling four RCTs (n = 11 816) confirmed a 25% reduction in the composite of MI, stroke, or cardiovascular death (HR 0.75, 95% CI 0.61–0.92) and a 33% reduction when revascularisation was included (HR 0.67, 95% CI 0.55–0.82). The stroke reduction was particularly striking at 46% (HR 0.54, 95% CI 0.34–0.86). These benefits are comparable in relative magnitude to those seen with PCSK9 inhibitors and canakinumab, though achieved with a far less expensive oral agent.
The CLEAR-SYNERGY Neutral Result and What It Means
The 2025 CLEAR-SYNERGY trial (n = 7062) — the largest colchicine cardiovascular trial to date — found no significant benefit for the primary composite MACE endpoint (9.1% vs 9.3%; HR 0.99, 95% CI 0.85–1.16). This neutral result requires careful interpretation. Several factors distinguish CLEAR-SYNERGY from the positive trials: it used a higher initial dose (0.5 mg twice daily, later reduced to once daily due to discontinuation), enrolled patients immediately during ACS hospitalisation rather than in the stable or early post-MI phase, and was conducted substantially during the COVID-19 pandemic. Notably, hsCRP levels in the colchicine arm of CLEAR-SYNERGY remained above 2.0 mg/L — a threshold below which previous data (CANTOS) suggest anti-inflammatory benefit occurs. The 2025 updated meta-analysis incorporating CLEAR-SYNERGY nonetheless found the overall 25% MACE reduction with colchicine was preserved.
No colchicine trial has demonstrated a reduction in all-cause mortality. In LoDoCo2, there were numerically more non-cardiovascular deaths in the colchicine group (an imbalance that did not reach statistical significance). The smaller COPS trial found a statistically significant increase in non-cardiovascular death with colchicine, though this trial was underpowered and had a short follow-up. The 2021 Fiolet meta-analysis found that colchicine was associated with a nominal increase in non-cardiovascular death, counterbalanced by a lower incidence of cardiovascular death, yielding a neutral effect on all-cause mortality (HR 1.08, 95% CI 0.71–1.62). Reassuringly, neither COLCOT (HR 0.98, 95% CI 0.64–1.49) nor the much larger CLEAR-SYNERGY (HR 0.90, 95% CI 0.73–1.12) showed an increase in all-cause mortality. The mortality question remains unresolved but is currently being tracked in ongoing pharmacovigilance.
At the 0.5 mg daily dose without a loading dose, colchicine is generally well-tolerated. In LoDoCo2 and COLCOT, diarrhoea occurred in approximately 10% of colchicine-treated patients versus 9% on placebo — a clinically modest difference. Nausea, flatulence, and myalgias occurred at similarly low differential rates. COLCOT did find a higher rate of pneumonia as a serious adverse event in the colchicine group (0.9% vs 0.4%), a finding consistent with colchicine’s immunomodulatory effects. Leukopenia and thrombocytopenia were rare (<0.5%). Crucially, colchicine has a narrow therapeutic index and clinically significant interactions with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) and P-glycoprotein inhibitors — drugs that can elevate colchicine levels to toxic concentrations. The FDA label contraindicates concurrent use. For family physicians, common interactions to flag include azithromycin (temporary colchicine hold advised) and certain statins metabolised via CYP3A4, though the combination with most statins appears safe based on trial data.
A 2025 secondary analysis of LoDoCo2 explored colchicine’s benefit across baseline risk strata. The relative risk reduction with colchicine was consistent across all risk levels, but as expected, the absolute benefit was greatest in patients at highest baseline risk. Both COLCOT and LoDoCo2 demonstrated consistent effects in patients with and without diabetes. The 2023 AHA/ACC guideline recommends limiting colchicine use to patients who remain at very high risk despite maximal guideline-directed medical therapy — essentially those with persistent residual risk. Some experts advocate measuring hsCRP to identify patients with residual inflammatory risk (hsCRP ≥2 mg/L on statin therapy) as a selection strategy, though the trials themselves did not require elevated hsCRP for enrolment and the FDA label does not mandate testing.
All completed colchicine cardiovascular trials enrolled patients with established ASCVD — the current evidence supports secondary prevention only. The FDA indication does include patients “with multiple risk factors for cardiovascular disease,” which potentially extends to high-risk primary prevention populations, but no RCT has specifically tested colchicine in a primary prevention cohort. Whether colchicine benefits patients with subclinical atherosclerosis (e.g., elevated coronary artery calcium scores) but no clinical events is unknown. Family physicians should be aware that prescribing colchicine for primary prevention is not currently supported by trial-level evidence.
Quality & Consistency of Evidence
What the Evidence Does Not Show
Several clinically important questions remain unanswered despite the growing colchicine evidence base.
Optimal patient selection strategy. Whether hsCRP testing should guide colchicine prescribing is debated but untested in a prospective trial. The landmark trials did not require elevated inflammatory markers for enrolment, yet sub-analyses suggest the benefit may be amplified when on-treatment hsCRP falls below 2 mg/L. Whether family physicians should measure hsCRP before and after initiation to confirm anti-inflammatory response remains a clinical judgement call without guideline consensus.
Duration of therapy. The LoDoCo2 and COLCOT trials had median follow-up of 29 and 23 months, respectively. Whether colchicine’s cardiovascular benefit is maintained — or potentially changes in character — over 5, 10, or more years of continuous use is unknown. The non-cardiovascular mortality signal, in particular, requires longer-term pharmacovigilance to fully characterise.
Immediate use in acute coronary syndrome. Both COPS and CLEAR-SYNERGY, which initiated colchicine during the acute ACS hospitalisation, showed neutral or less favourable results compared with LoDoCo2 and COLCOT, which enrolled patients in the stable phase. Whether colchicine is beneficial, neutral, or potentially harmful when initiated in the hyperacute setting remains unresolved.
Real-world adherence and effectiveness in primary care. All trials were conducted in cardiology research settings with structured follow-up. Whether colchicine’s benefit translates to routine primary care prescribing — where medication adherence, polypharmacy management, and drug interaction monitoring may differ — has not been studied.
Practical Implications
Based on the current evidence, the following considerations may inform prescribing decisions for family physicians managing patients with established ASCVD. These reflect synthesised trial data and guideline positions — they are evidence-based considerations, not directive recommendations.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong (MACE reduction in stable CAD and post-MI) / Limited (Acute ACS initiation and primary prevention)
Two large, well-designed RCTs and multiple confirmatory meta-analyses provide strong evidence that colchicine 0.5 mg daily reduces cardiovascular events in patients with established CAD. The effect is robust, consistent, and now FDA-approved. Evidence for initiation during acute ACS is conflicting, and evidence for primary prevention does not exist.
The “strong” grade for MACE reduction means family physicians can prescribe colchicine with confidence for appropriately selected patients with stable coronary disease or stabilised post-MI — particularly those with evidence of residual inflammatory risk. The “limited” grades for acute initiation and primary prevention mean these uses should not be assumed to be beneficial based on current data.
- Low-dose colchicine (0.5 mg daily) reduces major cardiovascular events by 23–31% when added to optimised GDMT in patients with stable CAD or stabilised post-MI.
- The 2023 AHA/ACC guideline recommends colchicine as a Class 2b option for very high-risk patients with chronic coronary disease on maximal therapy.
- No reduction in all-cause mortality has been demonstrated; a persistent but statistically non-significant signal toward increased non-cardiovascular death in some trials requires ongoing monitoring.
- Drug interaction screening (CYP3A4/P-gp inhibitors), renal/hepatic function assessment, and patient education about temporary holds during interacting antibiotic courses are essential prescribing safeguards.
- Evidence for colchicine in primary prevention or immediate use during acute coronary syndrome hospitalisation is insufficient to support these applications currently.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. DOI: 10.1056/NEJMoa2021372
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. DOI: 10.1056/NEJMoa1912388
- Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. DOI: 10.1016/j.jacc.2012.10.027
- Jolly SS, d’Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med. 2025;392:633–642. DOI: 10.1056/NEJMoa2404372
- Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–1900. DOI: 10.1161/CIRCULATIONAHA.120.050771
- Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–2775. DOI: 10.1093/eurheartj/ehab115
- Fiolet ATL, et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025;46(26):2552–2561. DOI: 10.1093/eurheartj/ehaf283
- Ridker PM, Nidorf SM, Ben-Chetrit E. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(7):648–660. DOI: 10.1016/j.jacc.2023.05.055
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Circulation. 2023;148(9):e9–e119. DOI: 10.1161/CIR.0000000000001168
- Mohammadnia N, et al. Cardiovascular benefit of colchicine in relation to baseline risk: a secondary analysis of the LoDoCo2 trial. J Am Heart Assoc. 2025;14:e038687. DOI: 10.1161/JAHA.124.038687
- Sarraju A, et al. Potential impact of colchicine on atherosclerotic cardiovascular disease in the United States. J Am Heart Assoc. 2025;14:e037789. DOI: 10.1161/JAHA.124.037789
- Lodoco (colchicine) tablets prescribing information. Parsippany, NJ: Agepha Pharma USA, LLC; 2023.